I am no stats professor but I believe the DMX200 vs placebo reduction should be 2%, not 12%. This is the problematic area - the part where the legacy effect argument lies.
I thought the average 14% reduction for DMX200 vs baseline is very close to statistical significance (15%) but this is not observed in DMX200 vs placebo. I saw a post where one postulates that it is easy to plot this out and conclude whether there is any legacy effect or not - I don't think it is that simple and straightforward - Even if the graph visually tells you there is a correlation, it is not necessarily a legacy effect (cause) from DMX 200. I believe they will need to review medication, diet, etc.. before jumping to a conclusion. So, I thought they are being careful not to mislead the market unless they are fairly certain (not just by looking at numbers alone).
DXB Price at posting:
24.0¢ Sentiment: Hold Disclosure: Held
(20min delay)